COVID-19 Research Paper Volume 13, Issue 12 pp 15785—15800

Clinical characterization and therapeutic targets of vitamin A in patients with hepatocholangiocarcinoma and coronavirus disease

Prognostic value of CHOL/COVID-19-associated genes. (A) Univariate Cox analysis of 7 CHOL/COVID-19-associated genes, including MRC1, CP, ITGA5, SNCA, HARS1, ENPP1, and PLAU. (p B) Survival analysis indicated no difference in the overall survival between high- and low-risk groups of CHOL patients. (C) Analysis of patients’ risk score using Cox proportional hazards regression showed the increasing risk score in the CHOL patients with high risk. (D) Heatmap showed the overexpression of CP, HARS1 and PLAU in the CHOL patients with high risk as compared to those with low risk. (E) The CHOL patients from high-risk group had a poor overall survival rate as compared to those from low-risk group.

Figure 2. Prognostic value of CHOL/COVID-19-associated genes. (A) Univariate Cox analysis of 7 CHOL/COVID-19-associated genes, including MRC1, CP, ITGA5, SNCA, HARS1, ENPP1, and PLAU. (p < 0.05). Hazard ratio represented the correlation of the identified genes and CHOL. (B) Survival analysis indicated no difference in the overall survival between high- and low-risk groups of CHOL patients. (C) Analysis of patients’ risk score using Cox proportional hazards regression showed the increasing risk score in the CHOL patients with high risk. (D) Heatmap showed the overexpression of CP, HARS1 and PLAU in the CHOL patients with high risk as compared to those with low risk. (E) The CHOL patients from high-risk group had a poor overall survival rate as compared to those from low-risk group.